Melqart Asset Management (Uk) LTD Cerevel Therapeutics Holdings, Inc. Transaction History
Melqart Asset Management (Uk) LTD
- $1.54 Billion
- Q1 2024
A detailed history of Melqart Asset Management (Uk) LTD transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Melqart Asset Management (Uk) LTD holds 944,364 shares of CERE stock, worth $38.1 Million. This represents 2.59% of its overall portfolio holdings.
Number of Shares
944,364
Previous 286,393
229.74%
Holding current value
$38.1 Million
Previous $12.1 Million
228.73%
% of portfolio
2.59%
Previous 0.94%
Shares
2 transactions
Others Institutions Holding CERE
# of Institutions
227Shares Held
150MCall Options Held
939KPut Options Held
961K-
Bain Capital Investors LLC Boston, MA65.7MShares$2.65 Billion61.94% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$435 Million9.58% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.56MShares$304 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.46MShares$301 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$220 Million0.01% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Market Cap $6.28B
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...